Q32 Bio Depreciation & Amortization Growth & History (QTTB)
Q32 Bio's depreciation and amortization was $391,000 for fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $391,000 | −$96,000 | −19.71% |
| 2024 | 2024-12-31 | $487,000 | −$12,000 | −2.40% |
| 2023 | 2023-12-31 | $499,000 | −$794,000 | −61.41% |
| 2022 | 2022-12-31 | $1.3M | −$7.1M | −84.52% |
| 2021 | 2021-12-31 | $8.4M | $388,000 | +4.87% |
| 2020 | 2020-12-31 | $8.0M | $1.6M | +26.07% |
| 2019 | 2019-12-31 | $6.3M | $5.0M | +390.15% |
| 2018 | 2018-12-31 | $1.3M | $605,000 | +88.45% |
| 2017 | 2017-12-31 | $684,000 | — | — |
Q32 Bio quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $100,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $90,000 | −$29,000 | −24.37% |
| Q4 2025 | 2025-12-31 | $90,000 | — | — |
| Q3 2025 | 2025-09-30 | $100,000 | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $100,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $119,000 | −$4,000 | −3.25% |
| Q3 2024 | 2024-09-30 | $100,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $100,000 | −$100,000 | −50.00% |
| Q1 2024 | 2024-03-31 | $123,000 | −$4,000 | −3.15% |
| Q3 2023 | 2023-09-30 | $100,000 | −$200,000 | −66.67% |
| Q2 2023 | 2023-06-30 | $200,000 | −$100,000 | −33.33% |
| Q1 2023 | 2023-03-31 | $127,000 | −$221,000 | −63.51% |
| Q3 2022 | 2022-09-30 | $300,000 | −$1.8M | −85.71% |
| Q2 2022 | 2022-06-30 | $300,000 | −$1.8M | −85.71% |
| Q1 2022 | 2022-03-31 | $348,000 | −$1.7M | −83.27% |
| Q3 2021 | 2021-09-30 | $2.1M | $100,000 | +5.00% |
| Q2 2021 | 2021-06-30 | $2.1M | $100,000 | +5.00% |
| Q1 2021 | 2021-03-31 | $2.1M | $173,000 | +9.07% |
| Q3 2020 | 2020-09-30 | $2.0M | $300,000 | +17.65% |
| Q2 2020 | 2020-06-30 | $2.0M | $400,000 | +25.00% |
| Q1 2020 | 2020-03-31 | $1.9M | $641,000 | +50.63% |
| Q3 2019 | 2019-09-30 | $1.7M | $1.4M | +466.67% |
| Q2 2019 | 2019-06-30 | $1.6M | $1.4M | +700.00% |
| Q1 2019 | 2019-03-31 | $1.3M | $1.0M | +472.85% |
| Q3 2018 | 2018-09-30 | $300,000 | $100,000 | +50.00% |
| Q2 2018 | 2018-06-30 | $200,000 | $36,489 | +22.32% |
| Q1 2018 | 2018-03-31 | $221,000 | $90,844 | +69.80% |
| Q3 2017 | 2017-09-30 | $200,000 | — | — |
| Q2 2017 | 2017-06-30 | $163,511 | — | — |
| Q1 2017 | 2017-03-31 | $130,156 | — | — |
Q32 Bio depreciation and amortization trends
Over the last five fiscal years, Q32 Bio's depreciation and amortization decreased from $8.0M to $391,000, a change of −$7.6M. The latest reported quarter, Q2 2026, shows $100,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Q32 Bio source filings ↗